Bendamustine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Bendamustine
- Bendamustine: From Follicular Lymphoma and Other B-Cell Malignancies to Mantle Cell Lymphoma
Bendamustine: From Follicular Lymphoma and Other B-Cell Malignancies to Mantle Cell Lymphoma
One-Sentence Summary
Bendamustine is an alkylating chemotherapy agent originally used for follicular lymphoma, other mature B-cell neoplasms, acute lymphoblastic leukaemia and Richter syndrome. The TxGNN model predicts it may be effective for mantle cell lymphoma, with 40 clinical trials and 20 publications compiled for this direction, including several Phase 3 randomised trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Follicular lymphoma, mature B-cell neoplasms, acute lymphoblastic leukaemia, Richter syndrome (knowledge-graph indications; no approved indication text is available from local licences) |
| Predicted New Indication | Mantle cell lymphoma |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| New Zealand Market Status | Cancelled only (no currently valid authorisations) |
| Number of Authorizations | 5 (all cancelled) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, bendamustine is a bifunctional alkylating agent with a purine-analogue-like structure. It cross-links DNA and induces apoptosis in malignant B cells.
Mantle cell lymphoma is a mature B-cell neoplasm, so it belongs to the same disease class as the drug's original indications. Bendamustine plus rituximab (BR) is already an established backbone regimen. Recent trials add Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib on top of BR.
This is largely an extension within the same disease class rather than a true repurposing. The mechanistic fit is strong, but the novelty is limited.
Clinical Trial Evidence
The compiled data contain 40 trials for this prediction. The table lists the most relevant ones, prioritising completed or ongoing Phase 3 and bendamustine-focused Phase 2 trials.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00991211 | Phase 3 | Completed | 549 | First-line BR vs R-CHOP in advanced indolent and mantle cell lymphoma (non-inferiority, progression-free survival) |
| NCT00877006 | Phase 3 | Completed | 447 | BRIGHT study: BR vs R-CVP or R-CHOP in first-line indolent NHL or MCL |
| NCT01776840 | Phase 3 | Completed | 523 | Ibrutinib added to BR in patients aged 65+ with newly diagnosed MCL |
| NCT02972840 | Phase 3 | Active, not recruiting | 635 | Acalabrutinib plus BR vs placebo plus BR in untreated MCL |
| NCT06363994 | Phase 3 | Recruiting | 476 | Orelabrutinib plus BR vs BR in treatment-naive MCL |
| NCT06084936 | Phase 3 | Recruiting | 182 | Glofitamab vs investigator's choice (BR or R-Len) in relapsed/refractory MCL |
| NCT00891839 | Phase 2 | Completed | 45 | BR in relapsed/refractory MCL |
| NCT00740415 | Phase 2 | Completed | 39 | First-line treatment in elderly MCL patients (bortezomib-based chemoimmunotherapy) |
| NCT04115631 | Phase 2 | Active, not recruiting | 360 | Three BR-based arms (with high-dose cytarabine and/or acalabrutinib) in untreated MCL, age 70 or younger |
| NCT03834688 | Phase 2 | Completed | 33 | BR plus venetoclax in untreated MCL over 60 years |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23433739 | 2013 | RCT (Phase 3) | Lancet | BR vs R-CHOP as first-line treatment in indolent and mantle cell lymphoma (non-inferiority) |
| 24591201 | 2014 | RCT (Phase 3) | Blood | BRIGHT study: BR vs R-CHOP/R-CVP in treatment-naive indolent NHL or MCL |
| 30811293 | 2019 | Cohort follow-up | J Clin Oncol | BRIGHT 5-year follow-up data |
| 35657079 | 2022 | RCT | N Engl J Med | Ibrutinib plus BR and rituximab maintenance in older patients with untreated MCL |
| 40311141 | 2025 | RCT | J Clin Oncol | Acalabrutinib plus BR in untreated MCL; seeks to improve on ibrutinib's toxicity profile |
| 41052510 | 2025 | RCT (Phase 2/3) | Lancet | ENRICH: ibrutinib-rituximab vs immunochemotherapy (R-CHOP or BR) in patients aged 60+ |
| 32985902 | 2021 | RCT design | Future Oncol | Phase 3 design of zanubrutinib plus rituximab vs BR in transplant-ineligible MCL |
| 32126141 | 2020 | Phase 2 (pooled) | Blood Adv | Rituximab-bendamustine followed by rituximab-cytarabine induction in transplant-eligible MCL |
| 40975105 | 2025 | Phase 2 | Lancet Haematol | Rituximab, bendamustine and cytarabine followed by venetoclax in older, high-risk MCL |
| 41132246 | 2025 | Guideline | HemaSphere | EHA-EU MCL network guidelines for diagnosis and treatment |
New Zealand Market Information
All five authorisations are cancelled, so no bendamustine product is currently marketed in New Zealand under these licences. The data compiled for this report contain no approved indication text for these licences.
| Authorization Number | Product Name | Dosage Form | Status |
|---|---|---|---|
| 2524058 | Baxter | Inj 1 mg for ECP | Cancelled |
| 2691434 | Bendamustine Sandoz | Inj 25 mg vial | Cancelled |
| 2691442 | Bendamustine Sandoz | Inj 100 mg vial | Cancelled |
| 2483807 | Ribomustin | Inj 25 mg vial | Cancelled |
| 2483793 | Ribomustin | Inj 100 mg vial | Cancelled |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating agent) |
| Myelosuppression Risk | High (the knowledge graph links the drug to neutropenia, thrombocytopenia, agranulocytosis and anaemia) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count with differential, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindication signals (knowledge graph, not label text): liver failure, liver disease, kidney disease, gallbladder disease, pyoureter, thrombocytopenia, neutropenia, agranulocytosis, anaemia and macrocytic anaemia.
- Drug Interactions: 100 interactions were identified. Major-level interactions include deferiprone and samarium (153Sm) lexidronam. Moderate-level interactions include omeprazole, esomeprazole, cimetidine, caffeine, mercaptopurine, deferasirox, ticlopidine, roflumilast and chloramphenicol. Other moderate-level examples include obeticholic acid, palifermin and strontium-89 chloride.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 randomised trials (NCT00991211, NCT00877006, NCT01776840) and high-quality publications support bendamustine-rituximab in mantle cell lymphoma. However, the drug has no currently valid New Zealand authorisation, and package insert safety data are missing.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A regulatory pathway plan for re-establishing a bendamustine product in New Zealand
- A myelosuppression and infection monitoring plan, plus dose guidance for hepatic and renal impairment
Other Predicted Indications (Brief Notes)
| Rank | Predicted Indication | Evidence Level | Recommendation | |------|------|------|------| | 9 | MALT lymphoma | L2 | Proceed with Guardrails (Phase 2 BR trial with 60 patients; Phase 3 trials withdrawn or terminated) | | 3 | Hodgkin lymphoma | L3 | Research Question (early-phase evidence only) | | 5 | Small intestinal MALT lymphoma | L3 | Research Question (evidence inherited from generic lymphoma trials) | | 4 | Small intestinal Burkitt lymphoma | L3 | Hold (no entity-specific evidence) | | 7, 8 | Breast MALT lymphoma, tonsillar lymphoma | L4 | Hold (case reports only) | | 2 | Chronic myelogenous leukaemia, BCR-ABL1 positive | L4 | Hold (no clear mechanistic rationale) | | 6, 10 | Thyroid MALT lymphoma, relapsing-remitting multiple sclerosis | L5 | Hold (prediction only, no supporting studies) |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.